Laidlaw Analyst Recommendations & Stock Picks This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Laidlaw. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Laidlaw.MarketBeat Brokerage Ranking: Subscribe to MarketBeat All Access for the recommendation accuracy ratingAverage 12-Month ROI of Buy Recommendations: Subscribe to Unlock Country All Countries United States(NYSE & NASDAQ) United States(All Exchanges) Canada United Kingdom Sector All Sectors Aerospace Auto/Tires/Trucks Basic Materials Business Services Computer and Technology Construction Consumer Discretionary Consumer Goods Consumer Staples Finance Industrials Medical Miscellaneous Multi-Sector Conglomerates Energy Retail/Wholesale Services Transportation Utilities All Market Caps Large Cap ($10B+) Medium Cap ($2B-$10B) Small Cap (<$2B) Market Cap MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.Available with a MarketBeat All Access SubscriptionMarketRank™Upgrade to All Access to use the All Ranks Filter Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.Available with a MarketBeat All Access SubscriptionMedia SentimentUpgrade to All Access to use the All Sentiments Filter Analyst consensus is the average investment recommendation among Wall Street research analysts.Available with a MarketBeat All Access SubscriptionAnalyst ConsensusUpgrade to All Access to use the All Ratings Filter Export to Excel CompanyCurrent PriceReport DateAnalystActionRatingPrice TargetDetailsActionsSNTISenti Biosciences$1.68-1.2%6/6/2025Yale JenInitiated CoverageBuy$5.00View details for Laidlaw rating of Senti Biosciences (NASDAQ:SNTI) on 6/6/2025ICADicad$3.874/17/2025Yale JenReiterated RatingBuy -> HoldView details for Laidlaw rating of icad (NASDAQ:ICAD) on 4/17/2025SLNOSoleno Therapeutics$86.00-0.5%3/27/2025Yale JenBoost Price TargetBuy -> Buy$75.00 -> $105.00View details for Laidlaw rating of Soleno Therapeutics (NASDAQ:SLNO) on 3/27/2025NVCTNuvectis Pharma$6.80-2.3%3/17/2025Yale JenInitiated CoverageBuy$19.00View details for Laidlaw rating of Nuvectis Pharma (NASDAQ:NVCT) on 3/17/2025ABVXAbivax$71.94+0.2%7/29/2024-Initiated CoverageBuy$48.00View details for Laidlaw rating of Abivax (NASDAQ:ABVX) on 7/29/2024PHGEBiomX$0.39-46.8%5/28/2024-Initiated CoverageBuy$25.00View details for Laidlaw rating of BiomX (NYSEMKT:PHGE) on 5/28/2024CINGCingulate$5.10-1.5%12/22/2023-DowngradeBuy -> HoldView details for Laidlaw rating of Cingulate (NASDAQ:CING) on 12/22/2023CINGCingulate$5.10-1.5%1/20/2022-Initiated CoverageBuy$170.00View details for Laidlaw rating of Cingulate (NASDAQ:CING) on 1/20/2022CRISCuris$1.63-1.8%7/29/2020-Initiated CoverageBuy$100.00View details for Laidlaw rating of Curis (NASDAQ:CRIS) on 7/29/2020SLNOSoleno Therapeutics$86.00-0.5%6/5/2020Yale JenReiterated RatingBuy$150.00View details for Laidlaw rating of Soleno Therapeutics (NASDAQ:SLNO) on 6/5/2020 Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. DCTHDelcath Systems$10.59-1.5%6/1/2020-Initiated CoverageBuy$19.00View details for Laidlaw rating of Delcath Systems (NASDAQ:DCTH) on 6/1/2020ALDXAldeyra Therapeutics$4.81-3.6%5/26/2020-Reiterated RatingBuy$30.00View details for Laidlaw rating of Aldeyra Therapeutics (NASDAQ:ALDX) on 5/26/2020SLNOSoleno Therapeutics$86.00-0.5%12/23/2019Francois BriseboisInitiated CoverageBuyView details for Laidlaw rating of Soleno Therapeutics (NASDAQ:SLNO) on 12/23/2019EYPTEYEPOINT PHARMACEUTICALS$9.71-1.1%11/4/2019-Initiated CoverageBuy$500.00View details for Laidlaw rating of EYEPOINT PHARMACEUTICALS (NASDAQ:EYPT) on 11/4/2019AVDLAvadel Pharmaceuticals$11.08+5.4%9/24/2019Francois BriseboisBoost Price TargetBuy$3.00 -> $6.00View details for Laidlaw rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 9/24/2019TLSATiziana Life Sciences$2.38-4.8%9/10/2019Francois BriseboisSet Price TargetBuy$20.00View details for Laidlaw rating of Tiziana Life Sciences (NASDAQ:TLSA) on 9/10/2019EBSEmergent Biosolutions$5.63-4.3%9/4/2019Francois BriseboisSet Price TargetBuy$72.00View details for Laidlaw rating of Emergent Biosolutions (NYSE:EBS) on 9/4/2019CLSDClearside Biomedical$0.38-7.8%8/13/2019-DowngradeBuy -> HoldView details for Laidlaw rating of Clearside Biomedical (NASDAQ:CLSD) on 8/13/2019AVDLAvadel Pharmaceuticals$11.08+5.4%8/12/2019Francois BriseboisUpgradeHold -> Buy$3.00View details for Laidlaw rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 8/12/2019SLNOSoleno Therapeutics$86.00-0.5%7/8/2019-Initiated CoverageBuy$150.00View details for Laidlaw rating of Soleno Therapeutics (NASDAQ:SLNO) on 7/8/2019HOTHHoth Therapeutics$1.31-1.9%5/20/2019-Initiated CoverageBuy$250.00View details for Laidlaw rating of Hoth Therapeutics (NASDAQ:HOTH) on 5/20/2019AVDLAvadel Pharmaceuticals$11.08+5.4%3/18/2019Francois BriseboisSet Price TargetHold$2.00View details for Laidlaw rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 3/18/2019BSGMBiosig Technologies$4.29-7.1%2/20/2019Francois BriseboisSet Price TargetBuy$110.00View details for Laidlaw rating of Biosig Technologies (NASDAQ:BSGM) on 2/20/2019ARCTArcturus Therapeutics$12.30+0.7%2/19/2019-Initiated CoverageBuyView details for Laidlaw rating of Arcturus Therapeutics (NASDAQ:ARCT) on 2/19/2019TLSATiziana Life Sciences$2.38-4.8%12/17/2018-Initiated CoverageBuy -> BuyView details for Laidlaw rating of Tiziana Life Sciences (NASDAQ:TLSA) on 12/17/2018CLSDClearside Biomedical$0.38-7.8%11/6/2018Francois BriseboisSet Price TargetBuy$5.00View details for Laidlaw rating of Clearside Biomedical (NASDAQ:CLSD) on 11/6/2018AVDLAvadel Pharmaceuticals$11.08+5.4%11/6/2018-DowngradeBuy -> Hold$6.00View details for Laidlaw rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 11/6/2018CLSDClearside Biomedical$0.38-7.8%7/16/2018-Initiated CoverageBuy$18.00View details for Laidlaw rating of Clearside Biomedical (NASDAQ:CLSD) on 7/16/2018VKTXViking Therapeutics$32.68+0.3%6/1/2018-Boost Price TargetBuy$10.00 -> $15.00View details for Laidlaw rating of Viking Therapeutics (NASDAQ:VKTX) on 6/1/2018FRXFennec PharmaceuticalsC$11.01-3.4%11/29/2017-Initiated CoverageBuyC$22.00View details for Laidlaw rating of Fennec Pharmaceuticals (TSE:FRX) on 11/29/2017FENCAdherex Technologies$7.84-4.2%11/29/2017-Initiated CoverageBuy -> Buy$22.00View details for Laidlaw rating of Adherex Technologies (NASDAQ:FENC) on 11/29/2017EYPTEYEPOINT PHARMACEUTICALS$9.71-1.1%11/8/2017-Initiated CoverageBuy$500.00View details for Laidlaw rating of EYEPOINT PHARMACEUTICALS (NASDAQ:EYPT) on 11/8/2017DRRXDURECT$1.84-1.9%10/20/2017-Lower Price TargetBuy -> Buy$30.00 -> $20.00View details for Laidlaw rating of DURECT (NASDAQ:DRRX) on 10/20/2017IONSIonis Pharmaceuticals$43.03+0.1%8/14/2017-Reiterated RatingBuy$65.00View details for Laidlaw rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 8/14/2017ICADicad$3.877/25/2017-Reiterated RatingBuy$11.00View details for Laidlaw rating of icad (NASDAQ:ICAD) on 7/25/2017OPKOPKO Health$1.19-7.0%1/3/2017-Reiterated RatingBuy$22.00 -> $19.00View details for Laidlaw rating of OPKO Health (NASDAQ:OPK) on 1/3/2017IONSIonis Pharmaceuticals$43.03+0.1%12/27/2016-Boost Price TargetBuy$59.00 -> $65.00View details for Laidlaw rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 12/27/2016AXONAxon Enterprise$742.47-1.7%12/20/2016-Initiated CoverageSell$7.50View details for Laidlaw rating of Axon Enterprise (NASDAQ:AXON) on 12/20/2016VKTXViking Therapeutics$32.68+0.3%8/11/2016-Lower Price TargetBuy$20.00 -> $10.00View details for Laidlaw rating of Viking Therapeutics (NASDAQ:VKTX) on 8/11/2016AVDLAvadel Pharmaceuticals$11.08+5.4%1/21/2016-Lower Price TargetBuy$30.00 -> $25.00View details for Laidlaw rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 1/21/2016Ex-Hedge Fund Manager Uncovers $100 Trillion Land Shift (Ad)Trump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to unlock federal lands, oil reserves, and buried minerals... all for profit. Trump's team is already executing the orders... and Wall Street legend Whitney Tilson is stepping forward to show you how to position before the deadline.Click here to see the full story.OPKOPKO Health$1.19-7.0%8/13/2015-Initiated CoverageBuy$22.00View details for Laidlaw rating of OPKO Health (NASDAQ:OPK) on 8/13/2015OPKOPKO Health$1.19-7.0%8/12/2015-Initiated CoverageBuy$22.00View details for Laidlaw rating of OPKO Health (NASDAQ:OPK) on 8/12/2015ALDXAldeyra Therapeutics$4.81-3.6%1/26/2015Yale JenInitiated CoverageBuy$30.00View details for Laidlaw rating of Aldeyra Therapeutics (NASDAQ:ALDX) on 1/26/2015IONSIonis Pharmaceuticals$43.03+0.1%12/9/2014-Boost Price Target$65.00View details for Laidlaw rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 12/9/2014IONSIonis Pharmaceuticals$43.03+0.1%11/25/2014-Reiterated RatingBuyView details for Laidlaw rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 11/25/2014IONSIonis Pharmaceuticals$43.03+0.1%8/12/2014-Initiated CoverageBuy$52.00View details for Laidlaw rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 8/12/2014IOVAIovance Biotherapeutics$2.68+4.3%6/30/2014-Initiated CoverageBuyView details for Laidlaw rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 6/30/2014SSYSStratasys$10.59-2.2%3/7/2014-Initiated CoverageBuy$145.00View details for Laidlaw rating of Stratasys (NASDAQ:SSYS) on 3/7/2014OMCLOmnicell$29.76-4.0%3/5/2014-Boost Price TargetBuy$29.00 -> $34.00View details for Laidlaw rating of Omnicell (NASDAQ:OMCL) on 3/5/2014SRDXSurmodics$36.03+0.4%2/25/2014-Initiated CoverageBuy$30.00View details for Laidlaw rating of Surmodics (NASDAQ:SRDX) on 2/25/2014OMCLOmnicell$29.76-4.0%1/28/2014-Boost Price TargetBuy$27.00 -> $29.00View details for Laidlaw rating of Omnicell (NASDAQ:OMCL) on 1/28/2014 MarketBeat Community Rating for LaidlawCommunity Ranking: 2.6 out of 5 (2.6 of 5 stars)Outperform Votes: 49,929 (Vote Outperform)Underperform Votes: 47,182 (Vote Underperform)Total Votes: 97,111MarketBeat's community ratings are surveys of what our community members think about Laidlaw and other research firms. Vote "Outperform" if you believe Laidlaw's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Laidlaw's recommendations will underperform the S&P 500 over the long term. You may vote once every thirty days. Stock Forecasts and Research Tools Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
